Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. They currently have $6.25 price target on the biotechnology company’s stock.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Separately, StockNews.com initiated coverage on shares of Kamada in a research report on Monday. They issued a buy rating for the company.
Kamada (NASDAQ:KMDA – Get Rating) last released its quarterly earnings data on Tuesday, March 15th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.09). Kamada had a negative net margin of 2.15% and a negative return on equity of 0.91%. The firm had revenue of $31.47 million during the quarter, compared to the consensus estimate of $22.24 million. During the same quarter in the prior year, the company earned $0.04 EPS. Sell-side analysts predict that Kamada will post 0.14 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in Kamada by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 25,878 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 1,856 shares during the period. Dimensional Fund Advisors LP boosted its stake in Kamada by 9.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 52,003 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 4,350 shares during the period. Wells Fargo & Company MN boosted its stake in Kamada by 1.5% in the 4th quarter. Wells Fargo & Company MN now owns 454,137 shares of the biotechnology company’s stock worth $2,988,000 after purchasing an additional 6,829 shares during the period. Goldman Sachs Group Inc. boosted its stake in Kamada by 24.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 49,564 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 9,701 shares during the period. Finally, Marshall Wace LLP acquired a new position in Kamada in the 4th quarter worth $73,000. Institutional investors and hedge funds own 20.41% of the company’s stock.
Kamada Company Profile (Get Rating)
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection.
- Get a free copy of the StockNews.com research report on Kamada (KMDA)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.